



Pathogenicity Interpretation in the Age of Precision Medicine

Chesapeake Room
Holiday Inn Baltimore Inner Harbour
Baltimore, MD, USA
6th October 2015

7.30 – 8.15 Registration
Speakers arrive and hand in presentations

8.15 – 8.20 **Introduction**
Marc Greenblatt

Session 1 Chair: Marc Greenblatt

8.20 – 8.45 **Computational methods for pathogenicity assessment (*exact title TBA*)**

Carlos Bustamante
Stanford University, USA

8.45 – 9.10 **Towards increasing the clinical relevance of computational methods to predict the consequence of human genetic variation**

Rachel Karchin
Johns Hopkins, USA

9.10 – 9.25 Discussion

9.25 – 9.35 **Semi-supervised learning for clinical variant interpretation**

Matthew D. Rasmussen
Counsyl, South San Francisco, USA

9.35 – 9.40 **Findings from the Critical Assessment of Genome Interpretation, a community experiment to evaluate phenotype prediction**

Steven Brenner
University of California, Berkeley, CA, USA

9.40 – 9.50	Diagnostic Role of Exome Sequencing in Immune Deficiency Disorders Steven Brenner University of California, Berkeley, CA, USA
9.50 – 10.00	The European Variation Archive: assessing data quality, integration with LOVD and addition of clinically relevant data Garry Saunders EMBL-EBI, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
10.00 - 10.10	Description Extractor: Automated HGVS-recommended sequence variant description Peter Taschner Depts of Human Genetics and Molecular Epidemiology, LUMC, and LIACS, University Leiden3, Leiden, Nederland
10.10 – 10.20	Rapid Fire Poster Presentations
10.20 – 10.30	COMPANY LECTURE Qiagen Title TBA
10.30 – 11.00	Qiagen Coffee Break & Poster Session
Session 2	Variant Nomenclature Chair: Steven Brenner
11.00 – 11.15	The HGVS recommendations to describe DNA, RNA and protein sequence Johan T. den Dunnen
11.15 – 11.30	Variant representation in a world of change Deanna Church
11.30 – 11.45	Working towards a combined ISCN and HGVS standard for the description of chromosome rearrangements Jean McGowan-Jordan
11.45 – 12.40	Evolution of nomenclature systems to create a standard that incorporates traditional HGVS nomenclature and genomic systems Panel Discussion: <ul style="list-style-type: none">• Johan T. den Dunnen (LUMC), Chair• Deanna Church (Personalis)• Fiona Cunningham (EBI)• Reece Hart (Invitae)

- Jean McGowan-Jordan (Chair, ISCN)

12.40 – 13.40 Lunch & HGVS Annual General Meeting

Session 3 Chair: Christophe Beroud

13.40 – 14.05 Predicting the pathogenicity of genetic variants in the DNA double-strand break repair pathway

Harry Ostrer

Albert Einstein College of Medicine, USA

14.05 – 14.30 Functional assays for assessment of variants of uncertain significance (VUS) in breast and ovarian cancer predisposition genes

Fergus Couch

Mayo Clinic, USA

14.30 – 14.45 Discussion

14.45 – 14.55 Rare non-synonymous variations in the human ferroportin iron transporter gene (haemochromatosis type 4): the quest for causal mutations

Gérald Le Gac

U1078, Brest, France

14.55 – 15.20 Experimental methods for pathogenicity assessment (*exact title TBA*)

Nicholas Katsanis

Duke University, USA

15.20 – 15.45 Systematically identifying pathogenic human variants using yeast

Fritz Roth

University of Toronto, Canada

15.45 – 15.55 Discussion

15.55 – 16.00 Meeting Summary

16.00 MEETING END IN TIME FOR ASHG PLENARY